In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus

Phase 2

Completed

• Conditions: Diabetes Mellitus, Type 2
• Interventions: Biological: placebo injection; Drug: GSK716155 subcutaneous injections

• Registration Number: NCT00354536
• Lead Sponsor: GlaxoSmithKline

Brief Summary

This study is a placebo-controlled study in patients with Type 2 Diabetes Mellitus to assess safety and tolerability parameters, the levels of GSK716155 in the bloodstream when it is given at the same dose 7 days apart, and the impact this medication has on various substances in the blood. Assessments include ECGs, vital signs, repeat blood sampling and monitoring of any side effects.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-02
• Study First Submitted: 2006-07-18
• Study First Submitted QC: 2006-07-18
• Study First Posted: 2006-07-20
• Primary Completion: 2006-09
• Study Completion: 2006-09
• Status Verified: 2016-10
• Last Update Submitted: 2016-10-24
• Last Update Posted: 2016-10-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
albiglutide placebo	placebo injection	placebo injection
albiglutide	GSK716155 subcutaneous injections	albiglutide injection

Primary Outcome Measures

Name	Time	Method
blood plasma levels of GSK716155	on days 2 & 9

Secondary Outcome Measures

Name	Time	Method
blood plasma levels of GSK716155	on days 2 & 9

Trial Locations

Locations (1)

GSK Investigational Site; 🇺🇸 San Antonio, Texas, United States